Holiness Sa Olasore, Akinniyi A Osuntoki, Olubunmi A Magbagbeola, Abdur-Rasheed B Awesu, Anthony A Olashore
{"title":"多巴胺转运蛋白基因(DAT1) 40bp 3' UTR VNTR多态性(rs28363170)与大麻使用障碍的关系","authors":"Holiness Sa Olasore, Akinniyi A Osuntoki, Olubunmi A Magbagbeola, Abdur-Rasheed B Awesu, Anthony A Olashore","doi":"10.1177/11782218231163696","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cannabis remains the most widely used illicit drug among Nigerians, often associated with psychiatric disorders. Since genetic predisposition has been implicated in substance use disorders, we, therefore, aimed at finding out the relationship between dopamine transporter gene (DAT1) polymorphism and cannabis use disorder.</p><p><strong>Methods: </strong>We recruited 104 patients from a tertiary psychiatric facility in Lagos, Nigeria, who were diagnosed with cannabis use disorder according to ICD-10 and 96 non-smokers as a comparative group. The smokers were screened with Cannabis Use Disorder Identification Test (CUDIT), and cannabis dependence was assessed with the Severity of Dependence Scale (SDS). Genotyping was carried out for the 40 bp 3' UTR VNTR of the DAT1 (rs28363170).</p><p><strong>Results: </strong>The frequencies of 9R/9R, 9R/10R, 10R/10R among non-smokers and smokers were 14 (14.3%), 25 (26.2%), 57 (59.5%) and 17 (16.3%), 54 (51.9%), 33 (31.7%) respectively. The genotype distribution was in Hardy Weinberg equilibrium (HWE) only in the smokers' population (χ² = 1.896, <i>P</i> = .166). Individuals with the 10R allele were almost twice as likely as the 9R carriers to smoke cannabis (OR = 1.915, 95% CI: 1.225-2.995). However, this polymorphism was not associated with the quantity of cannabis smoked, age at onset of smoking, CUDIT, and SDS scores.</p><p><strong>Conclusion: </strong>The DAT VNTR polymorphism was associated with cannabis smoking but not cannabis use disorder.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231163696"},"PeriodicalIF":2.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068503/pdf/","citationCount":"0","resultStr":"{\"title\":\"Association of Dopamine Transporter Gene (DAT1) 40 bp 3' UTR VNTR Polymorphism (rs28363170) and Cannabis Use Disorder.\",\"authors\":\"Holiness Sa Olasore, Akinniyi A Osuntoki, Olubunmi A Magbagbeola, Abdur-Rasheed B Awesu, Anthony A Olashore\",\"doi\":\"10.1177/11782218231163696\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Cannabis remains the most widely used illicit drug among Nigerians, often associated with psychiatric disorders. Since genetic predisposition has been implicated in substance use disorders, we, therefore, aimed at finding out the relationship between dopamine transporter gene (DAT1) polymorphism and cannabis use disorder.</p><p><strong>Methods: </strong>We recruited 104 patients from a tertiary psychiatric facility in Lagos, Nigeria, who were diagnosed with cannabis use disorder according to ICD-10 and 96 non-smokers as a comparative group. The smokers were screened with Cannabis Use Disorder Identification Test (CUDIT), and cannabis dependence was assessed with the Severity of Dependence Scale (SDS). Genotyping was carried out for the 40 bp 3' UTR VNTR of the DAT1 (rs28363170).</p><p><strong>Results: </strong>The frequencies of 9R/9R, 9R/10R, 10R/10R among non-smokers and smokers were 14 (14.3%), 25 (26.2%), 57 (59.5%) and 17 (16.3%), 54 (51.9%), 33 (31.7%) respectively. The genotype distribution was in Hardy Weinberg equilibrium (HWE) only in the smokers' population (χ² = 1.896, <i>P</i> = .166). Individuals with the 10R allele were almost twice as likely as the 9R carriers to smoke cannabis (OR = 1.915, 95% CI: 1.225-2.995). However, this polymorphism was not associated with the quantity of cannabis smoked, age at onset of smoking, CUDIT, and SDS scores.</p><p><strong>Conclusion: </strong>The DAT VNTR polymorphism was associated with cannabis smoking but not cannabis use disorder.</p>\",\"PeriodicalId\":22185,\"journal\":{\"name\":\"Substance Abuse: Research and Treatment\",\"volume\":\"17 \",\"pages\":\"11782218231163696\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068503/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Substance Abuse: Research and Treatment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/11782218231163696\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"SUBSTANCE ABUSE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Substance Abuse: Research and Treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11782218231163696","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0
摘要
导言:大麻仍然是尼日利亚人使用最广泛的非法药物,通常与精神疾病有关。由于遗传易感性与物质使用障碍有关,因此,我们旨在找出多巴胺转运蛋白基因(DAT1)多态性与大麻使用障碍之间的关系。方法:我们从尼日利亚拉各斯的一家三级精神病院招募了104名根据ICD-10诊断为大麻使用障碍的患者和96名非吸烟者作为对照组。采用大麻使用障碍识别测试(CUDIT)对吸烟者进行筛查,采用大麻依赖严重程度量表(SDS)对吸烟者进行大麻依赖评估。对DAT1 (rs28363170)的40 bp 3' UTR VNTR进行基因分型。结果:9R/9R、9R/10R、10R/10R在非吸烟者和吸烟者中的频率分别为14(14.3%)、25(26.2%)、57(59.5%)和17(16.3%)、54(51.9%)、33(31.7%)。吸烟人群基因型分布符合Hardy Weinberg平衡(HWE) (χ 2 = 1.896, P = 0.166)。携带10R等位基因的个体吸食大麻的可能性几乎是携带9R等位基因的个体的两倍(OR = 1.915, 95% CI: 1.225-2.995)。然而,这种多态性与吸食大麻的数量、开始吸烟的年龄、CUDIT和SDS评分无关。结论:DAT VNTR多态性与大麻吸食有关,与大麻使用障碍无关。
Association of Dopamine Transporter Gene (DAT1) 40 bp 3' UTR VNTR Polymorphism (rs28363170) and Cannabis Use Disorder.
Introduction: Cannabis remains the most widely used illicit drug among Nigerians, often associated with psychiatric disorders. Since genetic predisposition has been implicated in substance use disorders, we, therefore, aimed at finding out the relationship between dopamine transporter gene (DAT1) polymorphism and cannabis use disorder.
Methods: We recruited 104 patients from a tertiary psychiatric facility in Lagos, Nigeria, who were diagnosed with cannabis use disorder according to ICD-10 and 96 non-smokers as a comparative group. The smokers were screened with Cannabis Use Disorder Identification Test (CUDIT), and cannabis dependence was assessed with the Severity of Dependence Scale (SDS). Genotyping was carried out for the 40 bp 3' UTR VNTR of the DAT1 (rs28363170).
Results: The frequencies of 9R/9R, 9R/10R, 10R/10R among non-smokers and smokers were 14 (14.3%), 25 (26.2%), 57 (59.5%) and 17 (16.3%), 54 (51.9%), 33 (31.7%) respectively. The genotype distribution was in Hardy Weinberg equilibrium (HWE) only in the smokers' population (χ² = 1.896, P = .166). Individuals with the 10R allele were almost twice as likely as the 9R carriers to smoke cannabis (OR = 1.915, 95% CI: 1.225-2.995). However, this polymorphism was not associated with the quantity of cannabis smoked, age at onset of smoking, CUDIT, and SDS scores.
Conclusion: The DAT VNTR polymorphism was associated with cannabis smoking but not cannabis use disorder.